Frost & Sullivan, a business consulting firm involved in market research and analysis, conducted a thought leadership forum that brought together experts in the field of immuno-oncology. Follow their discussions about the current state of immunotherapies and the key challenges and future approaches to the targeted use of the immune system in cancer treatment.
Frost & Sullivan, a business consulting firm involved in market research and analysis, conducted a thought leadership forum that brought together experts in the field of CNS biomarkers. Follow their discussions about technological advancements in the field and future implications of the current research and development.
For the past 30 years, there has been one assumed culprit of Alzheimer’s disease (AD) — beta-amyloid. However, researchers have been unsuccessful in developing effective therapies targeting this protein. Understand the history of AD and beta-amyloid and see what other biomarkers are being investigated as potential therapeutic targets.
Ever wonder how football is linked to degenerative brain disease? Find out here. Also, learn about novel biomarkers for traumatic brain injury (TBI), the current state of TBI research, and promising new approaches for developing a robust diagnostic tool. Discover tests currently used to diagnose TBI and read about unusual techniques used to develop reliable biomarkers.
Small vesicles were identified over 50 years ago but scientists are still trying to understand their biology and role in disease. These vesicles have become relevant for monitoring, diagnosing, and treating complex diseases such as cancer. Yet, because of their small size compared to cells, they require intricate technologies to truly understand their impact in research. Learn about the various technologies used to study small vesicles and discover the power of flow cytometry for learning more about these valuable vesicles.
Since the first cytokine was identified over 60 years ago, a lot has been done to better understand these molecules. The use of multiplex immunoassays is one such way, though they aren’t considered quite as mainstream yet. Learn about how the SMARTS approach can be used to better align user experience to the performance characteristics of these multiplex assays and hopefully transition them to a more mainstream role in research.
Immuno-oncology, or cancer immunotherapy, research focuses heavily on the various types of cells and their behavior in cancer, so the use of flow cytometry to interrogate these cells is a no brainer. See how flow cytometry fits in this growing field of research and how it can help identify new targets and improve drug design to generate more effective and safer cancer therapeutics.
The advent of CRISPR as a gene editing tool appears to have revolutionized drug discovery and development in a very short time. CRISPR-Cas9 technology is also being utilized to target HIV, to mutate or cut out the provirus. Read about what’s new in potential treatments for HIV and the challenges facing the industry.
Cancer is one of the leading causes of death in the world and, due to an aging population, more and more people are diagnosed with cancer every year. Researchers are actively searching for treatment options in the form of potential biomarkers. Long noncoding RNAs (lncRNAs) have piqued the interest of researchers as a relatively new source of therapeutics. Learn more about lncRNAs and see how they can be used in cancer diagnosis and intervention.
Introducing data normalization into your western blotting workflow may sound unnecessary but it has proven to be a great way to ensure great results. Follow along as we break down some of the main takeaways from the first chapter in Dr. Oh’s popular wester blotting webinar series, including a unique method to ease normalization woes and worries.